Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Topas Therapeutics GmbH currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. Both of these actions are concentrated under 1 distinct examiner, STEINKE, SEAN JAMES, which centralizes the company's current prosecution efforts. Furthermore, these actions are localized within 1 distinct art unit, indicating a very specific technical focus for the company's active filings.
As the busiest examiner, STEINKE, SEAN JAMES is responsible for 2 pending office actions. These 2 actions represent the entirety of the company's current pending workload at the USPTO. The alignment of 1 examiner and 1 art unit suggests a highly streamlined prosecution path. For the practitioner, this means the outcome of the entire current portfolio depends on the relationship and interactions with this single examiner within their specific art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEINKE, SEAN JAMES | 2 | 12.5% | +42.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17904311 | AMPHIPHILIC POLYMERS AND THEIR USE FOR IMPROVED PRODUCTION OF NANOPARTICLES FOR THE TARGETED DELIVERY OF ANTIGENS | STEINKE, SEAN JAMES | 5d |
| 18684452 | Pharmaceutical Composition Comprising Nanoparticles for the Targeted Delivery of Antigens | STEINKE, SEAN JAMES | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17904311 | AMPHIPHILIC POLYMERS AND THEIR USE FOR IMPROVED PRODUCTION OF NANOPARTICLES FOR THE TARGETED DELIVERY OF ANTIGENS | STEINKE, SEAN JAMES | 5d |
| 18684452 | Pharmaceutical Composition Comprising Nanoparticles for the Targeted Delivery of Antigens | STEINKE, SEAN JAMES | — |
| Art Unit | Apps |
|---|---|
| 1619 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18684452 | Pharmaceutical Composition Comprising Nanoparticles for the Targeted Delivery of Antigens | STEINKE, SEAN JAMES | 1619 | §103§112 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 17904311 | AMPHIPHILIC POLYMERS AND THEIR USE FOR IMPROVED PRODUCTION OF NANOPARTICLES FOR THE TARGETED DELIVERY OF ANTIGENS | STEINKE, SEAN JAMES | 1619 | §102§103Other | Final Rejection | 5d | Pending | Aug 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTopas Therapeutics GmbH has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sean James Steinke has the most, with 2 of Topas Therapeutics GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
